# Post-marketing Clinical Trial of KAD-1229 in Patients With Type 2 Diabetes Mellitus

> **NCT02154347** · PHASE4 · COMPLETED · sponsor: **Kissei Pharmaceutical Co., Ltd.** · enrollment: 178 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** KAD-1229
- **DRUG:** Placebo
- **DRUG:** Insulin

## Key facts

- **NCT ID:** NCT02154347
- **Lead sponsor:** Kissei Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** 2016-07
- **Final completion:** —
- **Target enrollment:** 178 (ACTUAL)
- **Last updated:** 2019-09-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02154347

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02154347, "Post-marketing Clinical Trial of KAD-1229 in Patients With Type 2 Diabetes Mellitus". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02154347. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*